Windlas Biotech IPO

Windlas Biotech was established in 2001 and offers pharmaceutical innovation, large-scale production, and credible but reasonable products to distributors and clients all over the globe. Windlas Biotech IPO will hit the market on 04 August 2021.

About

At their 4 state-of-the-art production plants in Dehradun, Uttarakhand, India, they employs approximately 1500 staff.  They also have a marketing force and supply chain that covers nearly all of India’s regions.

To serve the semi-urban and remote populations, they market their own manufactured genuine nutraceutical, medicinal, and ayurvedic drugs at reasonable costs.

“Windlas Biotech Limited (Previously popular as Windlas Biotech Private Limited) is the firm’s legal name.”

Core

At Windlas, they pride themselves on their ability to innovate. For drug production, product delivery, and cost efficiency, they provide customers with customized innovation strategies and end-to-end distribution chain systems.

Their mission is to reduce their partners’ drug development time frames and minimize their period to launch. To fix technical problems and help in any distribution delays, they use their own research and development resources.

Windlas Biotech IPO

Windlas Biotech Limited, headquartered in Dehradun has submitted Draft Red Herring Prospectus(DRHP) to Securities and Exchange Board of India(SEBI) for initial public offering (IPO) of INR 401.53 crore on 14 May 2021.

The Offer includes a fresh equity of Rs. 165 crore and an offer to sell(OFS) up to 51.4 lakhs equity shares of Windlas Biotech with face value Rs 5 each by the promoters.

The management confirmed that it is in talks with its book running Banks to raise INR 50 million via a pre-IPO placement. According to the firm, the anchor investor offer phase will begin one business day prior to the IPO launch date.

They got approval from Securities and Exchange Board of India(SEBI) on 07 July, 2021 to float the initial public offering (IPO) in the market.

Financials Trends

Basic and Diluted Earnings Per Share (EPS)

Objects of the Issue

• Prepayment / repayment of all or a portion of the outstanding borrowings of the company to be availed on consolidated basis.
• To meet common corporate objectives.
• The firm will allocate a total of INR 475.6 million to finance additional working capital needs and INR 200 million to offset existing debt. Its gross unpaid borrowings were INR 321.6 million as of March 2021.

Basis of the offer

The following are some of the basic criteria and key strengths that go into determining the Offer Price:

• India ‘s top CDMO, focusing on the chronic therapeutic category.
• A diverse portfolio of complicated generics backed by strong R&D skills.
• Manufacturing facilities that are efficient and quality-compliant, with considerable entrance obstacles.
• Long-term partnerships with top pharmaceutical firms in India.
• A proven track record of financial success.
• Professional and technically trained staff with seasoned promoters and top management.

Windlas Biotech IPO Peer Comparison

There are no publicly traded firms in India with a range of products and services equivalent to theirs, or a scale of operations comparable to theirs.

Windlas Biotech IPO Details

Windlas Biotech IPO Tentative Date

The Windlas Biotech IPO opening date is 04 August 2021, and the closing date is 06 August 2021. The issue may list in 2021.

Windlas Biotech IPO Basis of Allotment

Windlas Biotech IPO Allotment Status

Allotment of equity stocks subject to the Fresh Issue and transfer of the Promoter Selling Shareholders’ OFS Stocks to the winning Bidders subject to the Offer for Sale. Nevertheless, the status of the allotment has yet to be revealed.

Here, you can find the Allotment Status of Windlas Biotech IPO.

Windlas Biotech IPO GMP

Windlas Biotech IPO Grey Market Premium is as follows and you can check GMP of other IPOs as well from links given below:

Check Out The GMP Of other IPOs

• Rolex Rings IPO
• Exxaro tiles IPO
• Nuvoco Vistas IPO
• Devyani International IPO

Windlas Biotech IPO Review

Windlas Biotech is a unique business model. However, volatility in financial performance is alarming about the company. You can subscribe with a long term view. Risk taking investors can apply for some decent listing gain & if you are risk cautions then you can avoid it for listing gains.

Windlas Biotech IPO Risk

• They rely on the success of their CDMO clients’ relationships. Any negative developments, as well as their failure to form or sustain such connections, might have a negative impact on their company.
• Their operations rely on research and development (“R&D”), and failing to invent innovative solutions to fulfil their customers’ expectations may have a negative impact on their business
• The current and future impact of the ongoing COVID-19 pandemic on their business.
• Their production facilities are all located in the same area. If they are unable to operate in this location, it may have a negative impact on the business.
• Any disruption in the supply of their raw materials might have a negative impact on overall operations.

Other Threats

• They are needed to obtain, renew, or maintain statutory and regulatory permissions and approvals in order to operate, and any delay or difficulty in doing so might have a negative effect on the business.
• Their company might suffer if any of their solutions cause, or are believed to induce, significant negative effects.
• Their production capacity may be underutilised, which might have a negative impact on their business.
• There are ongoing legal actions against their company and its directors. Any negative conclusion in these proceedings might have a negative impact on their company.
• One of our Independent Directors has previously been listed on the list of directors who were disqualified.

Windlas Biotech IPO Brokerage views

• Yes Securities : Subscribe with caution
• Choice Brokering: Subscribe
• Axis Securities: Subscribe with caution
• IIFL Securities: Subscribe
• Trade swift: Subscribe
• Anand Rathi : Subscribe
• ICICI Securities: Subscribe

Windlas Biotech IPO Subscription Status

Promoters

Promoters

• Ashok Kumar Windlass
• Hitesh Windlass
• Manoj Kumar Windlass
• AKW WBL Family Private Trust

Promoter Holding

• Windlas Biotech DRHP

Contact Details

Windlas Biotech Limited

40/1, Mohabewala Industrial Area,
Dehradun 248 110, Uttarakhand, India;
Tel: +91 135 6608000

E-mail: [email protected]

Website: www.windlasbiotech.com

Registrar

Link Intime India Private Limited
C-101, 1st Floor, 247 Park, Lal Bahadur Shastri Marg,
Vikhroli (West) Mumbai 400 083 Maharashtra
Tel: (+91 22) 4918 6200
E-mail: [email protected]
Website: www.linkintime.co.in

Lead Manager(s)

1. SBI Capital Markets Limited
2. IIFL Securities Limited
3. DAM Capital Advisors Limited

We hope we are able to answer all your questions about this IPO. If you don’t have a Demat account, open it now with Zerodha best trading app.

Disclaimer

The reference of IPO Grey Market Premium (IPO GMP) is only valid for the date specified in the header.
On the IPO Grey Market, we do not purchase or sell IPO forms.

The Kostak Rate is the profit earned by selling an IPO application (in an off-market transaction) to somebody else before the issue is allotted or listed.

Do not subscribe to an IPO based solely on the premium price, as it may alter at any time before to the listing. Only consider the fundamentals of the companies when subscribing.

The GMP rates for IPOs are based on market intelligence. Please keep in mind that these IPO GMP rates may vary by geography and market.

Note:

We do not engage in grey market trading or facilitate the purchase or sale of IPO forms.

What is grey Market?

The phrase “grey market” refers to an unofficial over-the-counter market where IPO applications and IPO stock are traded before the entity is listed on a stock exchange. This is a technique for dealers to help consumers who wish to sell their home before it goes on the market.

This is also a way to increase the listing fee and provide help for the issue prior to the listing. In the IPO grey market, there are two types of transactions that take place:

• IPO stocks are traded at a premium in the grey market.
• At a kostak, an IPO application is traded.

What is grey Market Premium?

The Grey Market Premium, or GMP, is the price at which IPO stock shares are exchanged in the grey market.

This could be correct or incorrect, implying that the grey market trading price is greater or cheaper than the issue price, depending on demand and supply for the stocks.

Typically, individuals who do not want to incur the risk of their shares not being allocated through an IPO can purchase shares on the grey market in the hopes of flipping them on the IPO for a profit.

What is Kostak?

The additional amount in rupees at which IPO applications are sold in the IPO Grey Market is known as kostak (or price of application). The bonus of a maximum lot retail application in an IPO is generally described as the ‘Kostak’ value.

The Kostak price is significant primarily before the offer is closed for subscription and the ultimate bidding status is made accessible to IPO participants. After the final auction status is known to investors, only a small percentage of IPO applications are exchanged.

‘Kostak’ is made for those who do not want to incur a risk on an IPO or gain from a listing.

Example:

Windlas Biotech IPO
Issue Price: Rs 306 Per Equity Share (Maximum Bid price)
Lot Size: 45
Grey Market Premium: Rs 220 to Rs 230
Kostak (Rs 13770): Rs 680 to Rs 720

This means Windlas Biotech IPO applications of Rs 13770 are being traded in IPO Grey Market at Rs 680 to Rs 720.

Despite the fact that this IPO’s Grey Market Premium is roughly 75% of the issue price, the ‘Kostak’ is just 5% of the application value.

Kostak rate

The Kostak rate is the fee received by an investor who sells his or her IPO application on the grey market. Regardless of allotment status, this is the money an individual stands to gain.

Subject to Sauda

The money that an investor stands to gain by selling his or her application for firm allotment is referred to as the subject to Sauda. Firm allocation is the important operative phrase here. The sauda will be cancelled if the applicant is not allotted.

When selling an IPO application in the grey market, the client and seller agree that the sale will only be legal if the seller receives the allocation. The deal is avoided if the seller does not get any stocks throughout the IPO procedure.

FAQ

Windlas Biotech IPO Opening Date?

Windlas Biotech IPO will open on 04 August 2021.

Windlas Biotech IPO Allotment Date?

Windlas Biotech IPO Allotment Date is 11 August 2021.

Windlas Biotech IPO Listing Date?

Windlas Biotech IPO Listing date is 17 August 2021

Windlas Biotech IPO GMP Today?

Windlas Biotech IPO Grey Market Premium is INR 65.

Windlas Biotech IPO Price Band?

Windlas Biotech IPO price Band is 0 to 0.